Professional Marketing briefs

Share this article:
Janssen is reassuming ex-US marketing rights for its Caeylx/Doxil cancer treatment. Merck has marketed the drug abroad since 1996. That deal expires at the end of the year, and marketing rights for the drug will revert to Janssen subsidiary Alza Corp. Janssen currently markets the product in the US, Japan and Israel under the Doxil brand.

Salesforce.com announced a partnership with Veeva Systems to bring Veeva's CRM applications to the pharma industry via the cloud computing firm's Force.com site. “Veeva is now salesforce.com's premier independent software vendor for sales force automation in the pharmaceutical and biotechnology segment,” said Veeva CEO Peter Gassner.

Physicians Interactive and OptimizerRx launched SampleMD, a virtual sampling program that allows docs to download sample vouchers, prescription co-pay coupons and other support information to their computers. A partnership allows each company to distribute the other's digital products and to develop a joint program that they hope will establish a “one stop shop” for vouchers, samples, co-pay programs and other patient support.
Share this article:
You must be a registered member of MMM to post a comment.
close

Next Article in Features

Email Newsletters

MM&M EBOOK: PATIENT ACCESS

Patient access to pharmaceuticals is a tale of two worlds—affordability has improved for the majority, while the minority is hampered by cost, distribution and red tape. To provide marketers with a well-rounded perspective, MM&M presents this e-book chock full of key insights. Click here to access it.

More in Features

Read the complete September 2014 Digital Edition

Read the complete September 2014 Digital Edition

Click the above link to access the complete Digital Edition of the August 2014 issue of MM&M, with all text, charts and pictures.

Medical marketing needs mainstream Mad Men

Medical marketing needs mainstream Mad Men

Agencies must generate emotional resonance with the target audience, not unlike Apple, Pepsi or Nike

Are discounts cutting out co-pays?

GSK's decision to cut Advair's price spurred some PBMs to put it back on formulary. Will drugmaker discounts diminish the need for loyalty programs? How can these programs stay relevant beyond giving co-pay assistance?